Paul A. Grayson
CIK: 0001861554
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Skye Bioscience, Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Mar 31, 2026SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
75K shares- - Feb 6, 2026SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
35K shares- - Feb 24, 2025SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
135K shares- - Nov 18, 2024SKYE
Skye Bioscience, Inc.
Sale(S)Direct86.2K shares at avg. $4.99$430K - Nov 15, 2024SKYE
Skye Bioscience, Inc.
Sale(S)Direct307 shares at avg. $5.55$2K - Oct 28, 2024SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
70K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 31, 2026 | SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 75,000 | - | - | Direct |
| Feb 6, 2026 | SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 35,000 | - | - | Direct |
| Feb 24, 2025 | SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 135,000 | - | - | Direct |
| Nov 18, 2024 | SKYE Skye Bioscience, Inc. | Sale(S) | 86,244 | $4.99 | $430,358 | Direct |
| Nov 15, 2024 | SKYE Skye Bioscience, Inc. | Sale(S) | 307 | $5.55 | $1,704 | Direct |
| Oct 28, 2024 | SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 70,000 | - | - | Direct |
1-6 of 6 transactions
About Grayson Paul A.
Grayson Paul A. (SEC CIK 0001861554) files insider reports with the SEC as Director of Skye Bioscience, Inc. (SKYE).
Signal8 holds 5 ownership filings by Grayson Paul A., all Form 4s, filed between Oct 30, 2024 and Apr 2, 2026. Those filings report 6 transactions, from Oct 28, 2024 to Mar 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Grayson Paul A.'s filings is in SAN DIEGO, CA.
Recent filings by Grayson Paul A.
- Mar 31, 2026: Grant or award of SKYE derivative securities (Form 4, code A).
- Feb 6, 2026: Grant or award of SKYE derivative securities (Form 4, code A).
- Feb 24, 2025: Grant or award of SKYE derivative securities (Form 4, code A).
- Nov 18, 2024: Open-market sale of SKYE shares (Form 4, code S).
- Nov 15, 2024: Open-market sale of SKYE shares (Form 4, code S).
Other insiders filing for Skye Bioscience, Inc. (SKYE)
- Schwab Andrew J., Director
- 5AM Partners VII, LLC, 10% Owner
- DHILLON PUNIT, Chief Executive Officer
- Sharp John P, Chief Financial Officer
- Smith Karen L., Director
- Twitty Christopher, Chief Scientific Officer